Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Debt: 2018-2022

Historic Total Debt for Theravance Biopharma (TBPH) over the last 3 years, with Jun 2022 value amounting to $396.1 million.

  • Theravance Biopharma's Total Debt rose 3.69% to $396.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $396.1 million, marking a year-over-year increase of 3.69%. This contributed to the annual value of $388.3 million for FY2021, which is 1.00% down from last year.
  • According to the latest figures from Q2 2022, Theravance Biopharma's Total Debt is $396.1 million, which was up 0.75% from $393.2 million recorded in Q1 2022.
  • Theravance Biopharma's 5-year Total Debt high stood at $396.1 million for Q2 2022, and its period low was $229.2 million during Q4 2019.
  • Over the past 3 years, Theravance Biopharma's median Total Debt value was $387.5 million (recorded in 2021), while the average stood at $386.0 million.
  • Per our database at Business Quant, Theravance Biopharma's Total Debt soared by 71.16% in 2020 and then dropped by 1.00% in 2021.
  • Over the past 5 years, Theravance Biopharma's Total Debt (Quarterly) stood at $229.5 million in 2018, then fell by 0.17% to $229.2 million in 2019, then soared by 71.16% to $392.2 million in 2020, then dropped by 1.00% to $388.3 million in 2021, then increased by 3.69% to $396.1 million in 2022.
  • Its Total Debt stands at $396.1 million for Q2 2022, versus $393.2 million for Q1 2022 and $388.3 million for Q4 2021.